title: Digoxin pharmacokinetics and perindopril in heart failure patients.
abstract: The influence of chronic perindopril treatment on digoxin pharmacokinetics was investigated in 10 patients with mild chronic heart failure under stable diuretic and digitalis treatment and normal renal function. Digoxin was administered at a dose of 0.125 mg/day (n = 2) or 0.250 mg/day (n = 8). The 24-hour steady-state digoxin profile was assessed before and after concomitant administration of perindopril for 1 month at doses of 2 mg once a day for the first 8 days and 4 mg once a day for the remaining 21 days. Chronic treatment with perindopril produced no significant effect on mean (+/- standard deviation) digoxin serum area under the curve for 24 hours (17.9 +/- 7.4 versus 16.3 +/- 4.4 ng/mL.h), peak digoxin concentration (1.3 +/- 0.54 versus 1.2 +/- 0.36 ng/mL), time to peak concentration (3 versus 4 hours), and apparent oral clearance of digoxin (237.7 +/- 109.6 versus 237.4 +/- 79.5 mL/min). Clinical and biologic tolerance of perindopril was good throughout the study. Chronic administration of perindopril did not alter steady-state digoxin kinetics in patients with mild chronic heart failure and normal renal function, indicating that no adaptation of the digoxin dose is required during co-prescription with perindopril in such patients.
authors.affiliation: Oldchurch Hospital, Romford, Essex, United Kingdom.
authors.forename: M J
authors.initials: MJ
authors.lastname: Vandenburg
authors.forename: J D
authors.initials: JD
authors.lastname: Stephens
authors.forename: G
authors.initials: G
authors.lastname: Resplandy
authors.forename: I M
authors.initials: IM
authors.lastname: Dews
authors.forename: J
authors.initials: J
authors.lastname: Robinson
authors.forename: P
authors.initials: P
authors.lastname: Desche
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D004077:Digoxin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D020913:Perindopril; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; D004077:Digoxin; D020913:Perindopril